Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Thomas P Lodise; Marc Scheetz; Joseph J Carreno; Henry Chambers; Vance Fowler Jr; Thomas L Holland

doi:10.1093/ofid/ofab651

Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

Open Forum Infect Dis. 2022 Jan 22;9(2):ofab651. doi: 10.1093/ofid/ofab651. eCollection 2022 Feb.

Authors

Thomas P Lodise¹, Marc Scheetz², Joseph J Carreno¹, Henry Chambers³, Vance Fowler Jr^{4

5}, Thomas L Holland^{4

5}

Affiliations

¹ Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
² Midwestern University Chicago College of Pharmacy, Chicago, Illinois, USA.
³ San Francisco General Hospital, San Francisco, California, USA.
⁴ Duke Clinical Research Institute, Durham, North Carolina, USA.
⁵ Duke University Medical Center, Durham, North Carolina, USA.

Abstract

Among patients with methicillin-resistant Staphylococcus aureus bacteremia, vancomycin-associated acute kidney injury increased as a function of the day 2 area under the curve (AUC), even for daily AUCs within the recommended therapeutic range (400-600). Further data are needed to determine if daily AUCs <400 can be maintained without compromising efficacy.

Keywords: MRSA; outcomes; pharmacokinetics; vancomycin.

Abstract

Grants and funding